TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01779050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02596191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle MRI

Intervention type: OTHER
Group type: OTHER
Intervention: blood samples analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples analysis
Study: NCT02751996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB 9200
Description: SB 9200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB 9200
Description: SB 9200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB 9200
Description: SB 9200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB 9200
Description: SB 9200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB 9200
Description: SB 9200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Study: NCT01157936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: daily dosage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily dosage
Study: NCT04767204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer co-delivered vocational rehabilitation service
Description: The services provided by the trained peers in the work training or problem-solving group, which integrates into a supported employment services
Study: NCT03232957

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 ug IT morphine
Description: Spinal block with bupivacaine and intrathecal morphine 50 ug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 100 ug IT morphine
Description: Spinal block with bupivacaine and intrathecal morphine 100 ug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No IT morphine
Description: Spinal block with bupivacaine and intrathecal morphine 0 ug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: intrathecal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: intrathecal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: intrathecal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5 isobaric bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5 isobaric bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.5 isobaric bupivacaine
Study: NCT04122898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
Study: NCT00819221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: capsules, oral, bd, 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: once every 4 weeks at 40mg/m2
Study: NCT03314753

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial

Intervention type: OTHER
Intervention: No interventions - retrospective data collection
Description: No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
Study: NCT02615366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01373437

Intervention type: DEVICE
Intervention: Ultrasonography (Sonosite )
Description: Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
Study: NCT03985631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention
Description: Rehabilitation sessions based on Tai Chi through telerehabilitation
Study: NCT02148692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Higher PEEP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower PEEP
Study: NCT00998660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa RC
Description: Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
Study: NCT02197715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-adaptive SAFE

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face SAFE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study: NCT03232047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined executive function and memory training
Description: Computerized combined executive function and memory training
Study: NCT01230944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen fundoplication

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Nissen fundoplication
Study: NCT02740777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Description: HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Description: HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Description: HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
Study: NCT02773355

Intervention type: DRUG
Intervention: liraglutide 3.0 mg
Description: Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
Study: NCT00840346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: 20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
Study: NCT00001596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 pills), three times daily.
Study: NCT04508868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation with Mental Imagery
Description: Session 1:~Provide psychoeducation about depression; Provide treatment rationale for BA; Provide rationale and instructions for activity log; Plan activities for coming week.~Session 2:~Review activity log; Discuss life goals and values; Plan activities aligned with life goals and values for coming week; Provide rationale for Mental Imagery (MI); Go through MI-exercise for one of the planned activities.~Session 3:~Review activity log; Troubleshoot any problems carrying out activities; Plan activities aligned with life goals and values for coming week; Go through MI-exercise for one of the planned activities.~Session 4:~Review activity log; Troubleshoot any problems carrying out activities; Review treatment; Stress the importance of continuing to engage in activities aligned with life goals and values; Referral to additional services if necessary.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minimal Attention Control Intervention
Description: Weekly call with follow-up of psychiatric symptoms and assessment of suicide risk.
Study: NCT04557397

Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: oral VEGFR inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: oral VEGFR inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: a synthetic triazole antifungal agent

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampin
Description: a semisynthetic antibiotic derivative of rifamycin SV
Study: NCT01098604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 28mm ceramic head group
Description: we performed THA using 28mm ceramic head in this group.
Study: NCT03401424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: improved Warren-type style
Description: Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y style
Description: Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
Study: NCT03449693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide Supplement
Description: Magnesium Oxide tablet
Study: NCT03883620

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengushield 1 mg/kg (Cohort 1) intravenous
Description: Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengushield 3 mg/kg (Cohort 2) intravenous
Description: Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 3 mg/kg (Cohort 2) intravenous
Description: Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengushield 7 mg/kg (Cohort 3) intravenous
Description: Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 7 mg/kg (Cohort 3) intravenous
Description: Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengushield 12 mg/kg (Cohort 4) intravenous
Description: Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 12 mg/kg (Cohort 4) intravenous
Description: Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
Study: NCT02341053

Intervention type: OTHER
Group type: OTHER
Intervention: Assisted Standing Treatment Program
Description: Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
Study: NCT03746873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Web
Description: The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52).
Study: NCT03675607

Intervention type: OTHER
Intervention: Complementary feeding behaviours
Description: Any kind of complementary feeding practice
Study: NCT05990972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation (FMT) is a therapeutic method to transplant the microbiota from the feces of healthy people into the intestinal tract of patients. This treatment aims to improve a range of diseases associated with the gut microbiota by restoring the balance of the gut microbiota.
Study: NCT01103011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0611
Description: Continuous delivery of ND0611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0611
Description: Solution of ND0611 delivered continuously
Study: NCT00996216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Description: Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
Study: NCT04279951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance exercise
Description: High-load and low-load resistance exercise two times per week for 10 weeks, preceded by 3 weeks of familiarization to training (high-load training)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1 gram of omega-3 per day for 20 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram of sunflower oleic oil per day for 20 weeks
Study: NCT01252108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: 300 mg SQ109 daily for 14 days
Study: NCT03770442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling with FES
Description: As described already

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy
Description: As described already
Study: NCT02033122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training
Description: the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breathing exercise
Description: Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
Study: NCT00468676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led case management
Description: The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
Study: NCT01054937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-203
Description: i.v. administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v. administration
Study: NCT03502668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 LD
Description: oral decitabine (LD) + cedazuridine (E7727)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 LD
Description: oral decitabine (LD) + cedazuridine (E7727)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 LD
Description: oral decitabine (LD) + cedazuridine (E7727)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727 SD
Description: oral decitabine (SD) + cedazuridine (E7727)
Study: NCT04439201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT02324374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocystoscopy During Colonoscopy
Description: Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocytoscope
Description: The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
Study: NCT03275051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safety and Efficacy assessments
Description: Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
Study: NCT02161627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saluda Medical External Trial System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saluda Medical External Trial System
Study: NCT02348827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family psychoeducation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support group
Study: NCT02415881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab IRDye 800
Description: Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci Firefly
Description: Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMAGE1 + ICG Hopkins telescope and/or VITOM
Description: IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
Study: NCT02715076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Temperature 19°C
Description: Ambient Temperature 19°C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Temperature 19°C
Description: Ambient Temperature 19°C